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Patient-derived xenograft (PDX) tumor models have emerged as a new approach to evaluate the effects of cancer
drugs on patients’ personalized tumor grafts enabling to select the best treatment for the cancer patient and
providing a new tool for oncology drug developers. Here, we report that human tumors engrafted in
immunodeficient mice are susceptible to formation of B-and T-cell PDX tumors. We xenografted human primary
and metastatic tumor samples into immunodeficient mice and found that a fraction of PDX tumors generated from
patients’ samples of breast, colon, pancreatic, bladder and renal cancer were histologically similar to lymphocytic
neoplasms. Moreover, we found that the first passage of breast and pancreatic cancer PDX tumors after initial
transplantation of the tumor pieces from the same human tumor graft could grow as a lymphocytic tumor in one
mouse and as an adenocarcinoma in another mouse. Whereas subcutaneous PDX tumors resembling human
adenocarcinoma histology were slow growing and non-metastatic, we found that subcutaneous PDX lymphocytic
tumors were fast growing and formed large metastatic lesions in mouse lymph nodes, liver, lungs, and spleen.
PDX lymphocytic tumors were comprised of B-cells which were Epstein-Barr virus positive and expressed CD45
and CD20. Because B-cells are typically present in malignant solid tumors, formation of B-cell tumor may evolve in
a wide range of PDX tumor models. Although PDX tumor models show great promise in the development of
personalized therapy for cancer patients, our results suggest that confidence in any given PDX tumor model
requires careful screening of lymphocytic markers.
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Numerous murine models have been developed to study human
cancer [1,2]. These models are used to investigate the factors involved
in malignant transformation, invasion, and metastasis, as well as to
examine response to therapy [1,2]. One of the most widely used
models is the human tumor xenograft [1,2]. The patient-derived
xenograft (PDX) tumor model approach is based on the transplan-
tation of primary or metastatic human tumors directly into highly
immunodeficient nonobese diabetic/severe combined immunodefi-
cient gamma (NSG) mice followed by continuous propagation of the
established heterotopic or orthotopic engraftment in mice [2–4].
Clinicians can evaluate the effects of cancer drugs on their patients’
personalized tumor grafts, enabling them to select the best treatment
for the cancer patient, and these models have evolved into a new tool
for developers of oncology drugs [2–8]. However, there are some
disadvantages and challenges of using mouse xenograft models. The
lack of T-cell immune response in immunodeficient mice makes
them vulnerable to T-cell–controlled infections, especially viral
infections [9,10], as well as to formation of lymphoproliferative
lesions [11,12]. Several recent studies revealed that human tumors
engrafted in NSG and NOG (NOD/Shi-scid/IL-2Rγnull) mice are
susceptible to Epstein-Barr virus (EBV)–associated lymphomagenesis
[11,12]. More than 90% of humans are infected with the EBV, and the
infection persists for life [13]. EBV, amember of the human herpesvirus
family, is the major cause of infectious mononucleosis and is associated
with several malignancies including nasopharyngeal carcinoma, gastric
carcinoma, Hodgkin lymphoma, Burkitt lymphoma, and posttrans-
plant lymphoma [13,14]. EBV can infect human B-cells, T-cells, NK
cells, and epithelial cells [15]. Because B-cells are typically present in
malignant solid tumors, formation of EBV-associated B-cell PDX
tumor may evolve in a wide range of PDX tumor models.
Here, we report that 32% of PDX tumors generated from the given
patient-derived tumor sample (including breast, colon, pancreatic,
bladder, and renal cancer) can progress into EBV-positive and highly
metastatic lymphocytic tumors. Our results suggest that human solid
tumors engrafted in NSG mice are susceptible to formation of B- and
T-cell PDX tumors and that thorough testing for lymphocytic
markers should be performed to ensure that the appropriate PDX
tumor model is used for the identification of personalized therapy for
each patient.
Materials and Methods
The research protocol was approved by Northwestern University
institutional review board, and all patients provided appropriate
informed consent. Human tumor tissue samples were obtained from
cancer patients and deidentified with six-digit numbers (Northwestern
University Pathology Core Facility [PCF] number). Freshly resected
human tumor samples were transplanted subcutaneously (SC) intoNSG
mice. Histopathological evaluation of tumor samples was performed by
board-certified pathologists (S.R. and J.W.). When SC PDX tumor
reached 1.5 cm in its largest dimension, the mouse was euthanized.
Subcutaneous PDX tumor and mouse spleen, lymph nodes (LN), liver,
and lung were collected; fixed in 10% formalin; and processed for
paraffin embedding. Paraffin sections (5 μm) were stained with
hematoxylin and eosin (H&E) for initial histopathological evaluation.
For immunohistochemical (IHC) staining, we used antibodies against
the leukocyte common antigen CD45 (monoclonal mouse anti-human,
final concentration 5 μg/ml; Dako, Carpinteria, CA), B-cell specific
surface protein CD20 (monoclonal mouse anti-human, final concen-tration 0.63 μg/ml; Dako, Carpinteria, CA), pan–T-cell specific marker
CD3 (polyclonal rabbit anti-human, final concentration 6 μg/ml; Dako,
Carpinteria, CA), and epithelial cell pan-cytokeratin (monoclonal mouse
anti-human, final concentration 0.5 μg/ml; Thermo Scientific,
Fremont, CA). IHC staining was visualized with Dako Envision+/
HRP kit according to the manufacturer’s recommended procedure.
In situ hybridization (ISH) for EBV-encoded RNA (EBER) was
performed on a Ventana Medical Systems automated slide stainer using
EBER probes and the Ventana ISH iVIEW Blue Detection Kit
according to manufacturer’s instructions.
Results
We established PDX tumors in NSG mice by SC transplan-
tation of freshly resected tumors obtained from breast, colon,
pancreatic, bladder, and renal cancer patients. At the first passage of
PDX tumor, we found that a fraction of PDX tumors generated from
patient samples of breast (one of three cases), colon (two of seven
cases), pancreatic (one of five cases), bladder (one of two cases),
and renal (one of two cases) cancer was histologically similar to
lymphocytic neoplasm (Figures 1–5). We found that 15 of 22 (68%)
PDX tumors (generated from patients’ samples of breast, colon,
pancreatic, bladder, and renal cancer) resembled histopathological
characteristics of original human carcinoma, whereas 7 of 22 (32%)
PDX tumors were comprised of lymphocyte-like cells. Some of SC
lymphocytic PDX tumors had rare inclusions of carcinoma cells.
Histologically, we found proliferation of a mixed population of
mononuclear cells, ranging from small lymphocytes or plasma cells to
large atypical lymphoid cells with pleomorphic nuclei and abundant
basophilic cytoplasm resembling lymphoblastoid cells, in lymphocytic
SC and metastatic PDX tumors (Figures 2, 4, and 5). Strikingly,
whereas SC PDX tumors resembling primary human carcinoma
histology were slow growing and nonmetastatic, we found that SC
lymphocytic PDX tumors were fast growing and formed large
metastatic lesions in mouse spleen, lymph nodes, liver, and lung
(Figure 1; Table 1). To differentiate between poorly differentiated
carcinoma and lymphocytic PDX tumor, we immunophenotyped
lymphocytic-like PDX tumors using immunohistochemical staining
for analysis of cytokeratin, CD45, CD20, and CD3 expression and
ISH for detection of EBV (EBER). Because EBV does not infect
rodent cells [16], EBER-positive staining was used as a marker of
infected human cells in mouse tissue. Immunohistochemical staining
showed that both human leukocyte common antigen CD45 and
B-cell antigen CD20 were expressed in EBER-positive lymphocytic
cells in 6 of 7 lymphoid PDX tumors and corresponding metastatic
lesions (Figures 4 and 5; Supplementary Figures 1–3). Our findings
of EBER-positive staining in lymphocytic PDX tumors suggest that
EBV-associated lymphomagenesis may lead to development of
human B-cell PDX tumors from xenografted human carcinomas
because of the high prevalence of EBV in humans and the presence of
EBV-infected B cells in solid human tumors.
In one case, we found that the first passage of breast PDX tumor
(PCF #373342) grew as an EBER-positive lymphocytic neoplasm in
one mouse and as a poorly differentiated adenocarcinoma in another
mouse after initial subcutaneous transplantation of the same sample
of metastatic pleural effusion obtained from a breast cancer patient
(Table 1; Figure 3A). B-cell origin of lymphocytic PDX tumor (PCF
#373342) was confirmed by IHC staining showing that lymphocytic
cells were cytokeratin negative, CD45 positive, and CD20 positive
(Table 1; Figure 4). The growth of the SC lymphocytic PDX tumor
Figure 1. Histopathological characterization of established PDX tumors. (A) Twenty-two PDX tumors were generated using
transplantation of human tumor samples obtained from 16 cancer patients. (B–E) Representative pictures of gross examination of
NSG mice bearing lymphocytic SC PDX tumors established from bladder (B), breast (C and D), and colon (E) human tumor samples.
Lymphocytic metastatic lesions were detected in mouse axillary lymph hodes (B and C), spleen (D), and liver (E). ▲, SC lymphoid PDX
tumor. M, metastasis.
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metastases, whereas the adenocarcinoma PDX from this same
patient’s pleural effusion did not metastasize (Table 1; Figure 4).
Further B-cell SC PDX tumor (PCF #373342) retransplantations and
passages showed similar aggressive B-cell PDX tumor growth and
development of distant metastasis in NSG mice. In another case, afterFigure 2. Lymphocytic SC PDX tumors are formed by B- or T-cells. Rep
from breast (A, B-cell SC PDX tumor), bladder (B, B-cell SC PDX tumo
human tumor samples.initial subcutaneous transplantation of a human primary pancreatic
tumor (PCF #379419) into NSG mice, one mouse developed
EBER-positive B-cell PDX tumor, whereas another mouse developed
an EBER-negative T-cell PDX tumor (Table 1; Figures 3B and 5, A
and B). T-cell origin of the lymphocytic PDX tumor (PCF #379419)
was confirmed by IHC staining showing that lymphoid cells wereresentative H&E images of lymphocytic SC PDX tumors established
r), and pancreatic (C, T-cell SC PDX tumor; D, B-cell SC PDX tumor)
Figure 3. Development of PDX tumors of different origin (lymphocytic
tumor and adenocarcinoma) from the same patient tumor sample. (A)
Breast PDX tumor model. First passage of breast PDX tumor (PCF
#373342) grew as lymphocytic neoplasm in one mouse and as a
poorly differentiated adenocarcinoma in anothermouse after the initial
SC transplantation of the same sample of ametastatic pleural effusion
obtained from a breast cancer patient. (B) Pancreatic PDX tumor
model. After initial SC transplantation of human primary pancreatic
tumor (PCF #379419) into NSG mice, one mouse developed a B-cell
PDX tumor, whereas another mouse developed an SC T-cell PDX
tumor. The T-cell PDX tumor did not grow after retransplantation,
whereas the B-cell PDX tumor progressed to a nonmetastatic
pancreatic PDX tumor (adenocarcinoma) after retransplantation.
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positive (Table 1; Figure 5B). T- and B-cell PDX tumors (PCF
#379419) developed distant metastases in mouse lung (T-cell), liverFigure 4. B-cell SC and metastatic PDX tumors established from met
#373342). Representative pictures of H&E, cytokeratin, CD45, CD20,
and lung. Lymphoid cells replaced original breast carcinoma cells (neg
of CD45-positive, CD20-positive (brown) leukocytes (B cell) with very
metastatic lymphocytic PDX tumors.(B-cell), and spleen (B-cell) (Figure 1; Table 1). Because of the small
inclusions of pancreatic carcinoma cells in the B-cell SC PDX tumor
(PCF #379419), further SC retransplantation of this tumor in nude
mouse led to the eventual development of a pancreatic PDX tumor
resembling moderately differentiated adenocarcinoma (Figure 3B).
Thus, retransplantation of SC B-cell PDX tumor from NSG to nude
mouse helps to clear SC PDX tumor from EBV-positive B cells
leading to formation of carcinoma (Figure 3B). Furthermore, we
found that PDX lymphocytic tumors did not grow in nude mice after
retransplantation from NSG mice. In nude mice, we observed that
PDX tumors could grow only as carcinomas. Probably, this
phenomenon can be explained by the fact that nude mice maintain
NK cells (participate in the immune response to EBV) which are not
available in highly immunodeficient NSG mice.
We found that the morphology and immunophenotype of tumor
cells in the metastatic lymphoid tumors corresponded to those found
in SC lymphocytic PDX tumors: EBER positive, CD45 positive,
CD20 positive and EBER negative, CD45 positive, CD20 negative,
CD3 positive in B- and T-cell PDX tumors, respectively (Table 1;
Figures 4 and 5). We found that EBER-positive metastatic PDX
B-cells could completely replace benign cells in mouse spleen, whereas
the foci of liver metastasis ranged from small periportal lesions to
diffuse infiltration lesions that altered hepatic histological architecture
(Figures 4 and 5; Supplementary Figures 1 and 2). We revealed that
mice with small lymphocytic metastases in the liver did not show
metastatic tumors in lung. Our findings also demonstrate that mouse
spleen is likely the most affected organ by the dissemination of
lymphoid metastatic cells from SC lymphocytic PDX tumor.
Our results suggest that PDX tumors engrafted in immunodefi-
cient NSG mice are susceptible to formation of aggressive and
metastatic lymphocytic PDX tumors and that thorough testing for
lymphocytic markers should be performed to ensure that appropriate
PDX tumor model is used for the identification of personalized
therapy for each patient.astatic pleural effusion obtained from a breast cancer patient (PCF
and EBER staining in B-cell SC and metastatic PDX tumors in liver
ative IHC staining for cytokeratin) in an SC PDX tumor. Proliferation
strong positive EBER staining (dark blue) was observed in SC and
Figure 5. Lymphocytic SC and metastatic PDX tumors established from primary tumor obtained from a pancreatic cancer patient (PCF
#379419). (A) Representative pictures H&E, cytokeratin, CD45, CD20, and EBER staining in B-cell SC and metastatic PDX tumors in liver
and spleen. Proliferation of CD45-positive, CD20-positive (brown) leukocytes (B cell) with strong positive EBER staining (dark blue) was
observed in SC and metastatic B-cell PDX tumors. (B) Representative pictures of H&E, cytokeratin, CD45, CD20, CD3, and EBER staining
in T-cell SC PDX tumors and lung metastasis. Proliferation of CD45-positive, CD20-negative (with inset of CD3-positive cells) (brown), and
EBER-negative leukocytes (T-cell) was observed in SC and metastatic T-cell PDX tumors.
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Although the use of immunodeficient mice contributes to better
efficiency of human tumor xenotransplantation [2], establishing PDX
tumor models in NSG mice has presented some challenges and
limitations. The lack of an intact immune system affects tumor
growth as well as metastasis [17]. The lack of T-cell immune response
in immunodeficient mice makes them vulnerable to T-cell–controlled
infections, especially viral infections [9,10]. It has been reported that
T-cells play a prominent role in controlling EBV-associated
oncogenesis [18]. Most people are infected with EBV [15]. Because
EBV can infect human B-cells and T-cells which are typically present
in solid malignant tumor [19], EBV-associated lymphocytic PDX
tumors may develop as a result of xenotransplantation of human solid
tumor to immunodeficient mice [11,12]. The potential development
of lymphocytic PDX tumors instead of an expected carcinoma may
significantly affect or mislead the efforts of clinicians to evaluate the
effects of cancer drugs on a particular patient’s tumor grafts, leading to
the selection of inappropriate clinical treatments for that patient.
Our study demonstrates that PDX tumor (developed from patient
samples of breast, colon, pancreatic, bladder, and renal cancer)
progressed to highly metastatic lymphocytic PDX tumor in 7 of 22
(32%) cases after initial SC transplantation of human tumor samples
in NSG mice. Our results are supported by a recently published studydemonstrating the development of EBV-associated B-cell PDX
tumors in 11 of 21 xenografts generated in NSG mice from 16
independent patient tumor samples of hepatocellular carcinoma [12].
However, subcutaneous B-cell PDX tumors in that study were not
metastatic in NSG mice [12]. Our results demonstrate that SC
lymphocytic PDX tumors are fast growing and form large metastatic
lesions in NSG mouse spleen, lymph nodes, liver, and lung. In
contrast to SC lymphocytic PDX tumors, we found that SC PDX
tumors resembling primary human carcinoma histology were slow
growing and nonmetastatic. These findings suggest that metastatic
lesions in lymph nodes, spleen, lung, or liver could serve as potential
markers of growing lymphocytic but not carcinoma PDX tumor after
initial SC transplantation of human tumor sample.
Our results show that EBV-associated lymphocytic PDX tumors
may be developed in NSG mice after initial transplantation of a wide
range of human carcinomas (breast, colon, pancreatic, bladder, and
renal). Another recently published study has demonstrated the
development of EBV-associated lymphocytic PDX tumors from
colorectal, gastric, breast, and lung tumor samples transplanted SC to
NOG mice [11]. In established PDX tumor models, the incidence of
lymphocytic PDX tumors was 56% (19 of 33), 76% (13 of 17), 50%
(2 of 4), and 67% (4 of 6) after initial transplantation of human
colorectal, gastric, breast, and lung tumors in NOG mice, respectively
Table 1. Analysis ofHistopathological Features of Subcutaneous andMetastatic Lymphocytic PDXTumors
Original Human
Tumor Type
Sample
ID
(PCF #)
PDX
Tumor
Staining
Cytokeratin CD45 CD20 EBER
Breast 373342 SC Negative Positive Positive Positive
Liver Negative Positive Positive Positive
Lung Negative Positive Positive Positive
LN Negative Positive Positive Positive
Colon 373888 SC Negative Positive Positive Positive
Liver Negative Positive Positive Positive
Spleen Negative Positive Positive Positive
Colon 366786 SC Negative (inclusions of
positive cancer cells)
Positive Positive Positive
Liver Negative Positive Positive Positive
Spleen Negative Positive Positive Positive
LN Negative Positive Positive Positive
Pancreatic
(CD3 negative)
379419 SC Negative Positive Positive Positive
Liver Negative Positive Positive Positive
Spleen Negative Positive Positive Positive
Pancreatic
(CD3 positive)
379419 SC Negative Positive Negative Negative
Lung Negative Positive Negative Negative
Bladder 380955 SC Negative Positive Positive Positive
Liver Negative Positive Positive Positive
Lung Negative Negative Negative Negative
Spleen Negative Positive Positive Positive
LN Negative Positive Positive Positive
Renal 366752 SC Negative Positive Positive Positive
Liver Negative Positive Positive Positive
Lung Negative Positive Positive Positive
LN Negative Positive Positive Positive
740 PDX Susceptible to Human Lymphocytic Tumors Bondarenko et al. Neoplasia Vol. 17, No. 9, 2015[11]. Histopathologically, Fujii et al. found lymphocytic metastatic
lesions inmouse spleen (all mice), liver, and kidney (1 of 6mice) obtained
from sixNOGmice which developed SC lymphocytic PDX tumors after
initial transplantation of human colorectal tumor samples [11].
Here, we also report the development of a T-cell PDX tumor after
initial transplantation of a human pancreatic carcinoma sample to NSG
mice. Our findings suggest that lymphocytic PDX tumors not only are
represented by EBV-associated B-cell tumors but may also originate
from EBV-negative T-cells (CD45 positive, CD3 positive, CD20
negative). We found that lymphocytic PDX tumors can form
hematogenous (spleen, liver, and lung) and lymphogenous (lymph
node) metastases (Table 1). However, the formation of SC and
metastatic T-cell PDX lesions might also reflect xenogeneic graft versus
host disease. A previous study described polyclonal disease-unrelated
cotransplanted donor human T-lymphocyte expansion in NSG
recipient mice [20]. In one study, donor T-cells mediated xenogeneic
graft versus host disease andmasked the engraftment of human AML in
mice [20]. Other studies demonstrated significant accumulation of
donor T-cells in spleen, whereas expression of homing receptors could
direct T-cells to skin [21], lung [22], and liver [23,24].
In conclusion, our results suggest that human tumors engrafted in
NSG mice are susceptible to formation of lymphocytic PDX tumors
and emphasize the need for thorough testing for lymphocytic markers
to ensure that the appropriate (nonlymphocytic) PDX tumor model is
used for the identification of personalized therapy for cancer patients.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2015.09.004.
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